Bio-Techne Corp at Stephens Investment Conference Transcript
All right. Good morning, everybody. Welcome to Day 3 of the Stephens 2022 Investment Conference. I'm Jacob Johnson, the life science tools and pharma services analyst here at Stephens. Thank you all for being here this morning. And thank you to Bio-Techne for joining us this morning. We have CFO, Jim Hippel. We have Will Geist, who is President of Protein Sciences, and we have Dave Clair from Corpdev/IR. We'll have questions in the middle of this. But Jim, I'll turn it over to you for any introductory comments you'd like to make, and then we'll jump into Q&A.
Yes. Thanks, Jacob. It's always a pleasure being at the Stephens conference, particularly here in Nashville, great place. Yes, opening comments, I'd say, is obviously, there's a lot of -- we're getting a lot of questions throughout the morning around what the macro environment is looking like and how that may impact our space and our company. And I think the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |